Digoxin may short Afib patients' lives, study says; Sun Pharma beats earnings estimates;

@FiercePharma: ICYMI earlier: Dendreon's debt plans could leave stockholders in the lurch. Article | Follow @FiercePharma

@EricPFierce: Merck KGaA has to rely on AZ as its pharma sales contract in Q2. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier: BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt. More | Follow @CarlyHFierce

> A new study found commonly used heart med digoxin may shorten the lives of patients with atrial fibrillation. Story (sub. req.)

> Sun Pharma's first-quarter results topped analyst estimates, pushing shares upward. Report

> Health Canada has OK'd GlaxoSmithKline's ($GSK) plan to address problems at its Quebec-based flu vaccine plant. More

Medical Device News

@FierceMedDev: Private hospitals in China are a priority for med tech Mindray. Story | Follow @FierceMedDev

@StacyALawrence: You're so fierce: A call for nominations of the top women in med tech. Editor's corner | Follow @StacyALawrence

@VarunSaxena2: In a 1st, CMS proposed to cover Cologuard Dx upon FDA approval, so it should get reimbursement faster. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: Lung transplant device wins FDA approval, holds potential for critically ill patients with cystic fibrosis. More from the NYT | Follow @EmilyWFierce

> Exact Sciences bags FDA approval and proposed CMS coverage for colorectal cancer screening test. Story

> FDA approves lung preservation device. Item

> Abbott wins Medicare coverage, new tech add-on payments for MitraClip cardiology device. Report

Biotech News

@FierceBiotech: In-depth piece on government's move to roll back oversight on biosecurity research. Article | Follow @FierceBiotech

@DamianFierce: ICYMI: Digging into the FDA's priority review voucher. Who's willing to pay big for one? Story | Follow @DamianFierce

@EmilyMFierce: Using experimental drugs and vaccines against Ebola is ethical, WHO panel says. Report from Science | Follow @EmilyMFierce

> Ear disease biotech Otonomy bags $100M in a booming IPO. Report

> When will Merck KGaA take the M&A plunge? More

> AstraZeneca clears some key PhIII hurdles with lesinurad gout combos. News

> Celltrion targets J&J's Remicade as biosimilars loom in the U.S. Story

Drug Delivery News

> Arrowhead updates TheStreet on clinical trial results of RNAi candidate for hepatitis B. Story

> Can insect venom be harnessed to fight cancer? Article

> Medicated electrospun fabric offers alternative delivery method for HIV-preventing drugs. More

> pH-sensing capsules that deliver optimal quantity of insulin under development. Story

> Oraya receives NIH grant to study use of its novel eye radiation tech against cancer. Article

Diagnostics News

> Novartis, LabCorp and more back Seventh Sense Biosystems' latest financing. Editor's corner

> Northern Ireland outfit advances a rapid but inexpensive heart attack test. Report

> GE Healthcare vet to take on Biocept's Dx reimbursement strategy. More

> Exact Sciences wins FDA approval and more for next-gen colon cancer Dx. Story

> Oxford Immunotec grabs remnants of Colorado rival for a bargain. Article

Pharma Marketing News

> Bye-bye, Incivek: Sovaldi forces Vertex drug off hep C market. Item

> BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt. Article

> Communiqué to sales reps: With today's docs, it's the medium and the message. More

> There's room for more parents, docs on Merck's Gardasil bandwagon. Story

> MannKind recruits Sanofi to hawk Afrezza in $925M marketing deal. Article

And Finally... Canada's government will donate doses of an experimental Ebola vaccine to the World Health Organization. More

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.